{"id":1538,"date":"2022-08-25T00:00:00","date_gmt":"2022-08-24T16:00:00","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&#038;p=1538"},"modified":"2025-10-28T11:20:59","modified_gmt":"2025-10-28T03:20:59","slug":"hanchorbio-inc-announces-closing-of-series-a-financing","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/zh-hans\/news\/hanchorbio-inc-announces-closing-of-series-a-financing\/","title":{"rendered":"HANCHORBIO INC. ANNOUNCES CLOSING OF SERIES-A FINANCING"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>August 5th, 2022 \u2013 HanchorBio Inc. (\u201cHanchorBio\u201d), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB\u2122) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.<\/p>\n","protected":false},"featured_media":0,"template":"","news-category":[],"class_list":["post-1538","news","type-news","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/news\/1538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=1538"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/news-category?post=1538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}